A possible vaccine against group A streptococcus has shown that it can generate immune responses without an injection in a mouse study. The research, led by the UK Medicines and Healthcare products Regulatory Agency in partnership with the GSK Vaccines Institute for Global Health, tested a candidate vaccine delivered through mucosal surfaces rather than by needle.
The findings are early-stage and do not establish that the vaccine prevents illness in people. But they address two longstanding challenges in Strep A vaccination: the absence of any licensed vaccine and the need for approaches that could be easier to use in settings where the disease burden is high.
A pathogen with no licensed vaccine
Group A streptococcus, often called Strep A, causes a large number of infections worldwide. Many are relatively mild, but complications can become severe and may lead to lasting disability or death. The source article estimates that Strep A causes more than 600 million infections globally each year and that associated complications account for more than 500,000 deaths.
The burden is especially significant in low- and middle-income countries. A vaccine that is affordable, practical to administer and capable of reaching the surfaces where infection begins could therefore have value beyond the clinical performance of the antigen itself.
There is currently no licensed Strep A vaccine. That makes the study a preclinical step in a broader effort, rather than an incremental update to an existing vaccination program.
Testing delivery through mucosal surfaces
The researchers examined delivery through the nose and under the tongue. These are mucosal routes: they target surfaces that are part of the body’s first encounters with many respiratory and throat pathogens. In mice, the candidate produced immune responses at mucosal surfaces as well as throughout the body.
The reported study included sublingual immunization, in which groups of mice received the candidate five times at weekly intervals. The paper was published in October 2026 in Human Vaccines & Immunotherapeutics.
That combination of local and systemic response is the central result. A conventional injected vaccine can produce strong systemic immunity, while mucosal vaccination is intended to add protection-oriented activity at the point where an infection may begin. The study does not prove clinical protection, and it does not establish how a human immune response would compare with the response in mice. It does, however, support further investigation of the route and formulation.
How the candidate is built
The formulation uses generalized modules for membrane antigens, known as GMMA. These are small membrane bubbles naturally released by bacteria. In this vaccine design, GMMA serve two roles: they carry the Strep A carbohydrate and help stimulate the immune response as an adjuvant.
The work was designed around a Strep A carbohydrate linked to GMMA. This approach aims to package the target antigen with a delivery and immune-stimulating platform, rather than relying on a conventional needle-delivered formulation alone.
According to Fatme Mawas, head of conjugate vaccines at MHRA, the results point to the potential of GMMA technology for affordable needle-free vaccines. The research team reported strong responses both at mucosal surfaces and systemically after nasal or sublingual delivery in the study animals.
Why needle-free delivery matters
A successful vaccine is not defined only by its biology. Administration, training requirements, equipment, supply chains and patient acceptance can all influence whether it reaches the people who need it. Delivery through the nose or beneath the tongue could simplify some parts of that equation if a comparable human product is eventually shown to be safe and effective.
The route could be particularly relevant where access to trained vaccinators or injection supplies is limited. It may also be useful for programs seeking to reduce barriers associated with needles. Those possible advantages remain prospective: they depend on subsequent studies, manufacturing development and evidence from human trials.
Researchers also see a potential antimicrobial-resistance benefit. If vaccination prevented infections before they occurred, it could reduce the need for antibiotics used to treat them. That is an indirect potential benefit, not an outcome demonstrated by this mouse experiment.
What comes next
The study should be read as preclinical evidence, not a near-term indication of availability. Mouse immune responses are an important research signal, but they are not a substitute for human safety, dosing and efficacy data. Researchers would need to establish whether the candidate can be manufactured consistently, determine an appropriate regimen, and test whether it protects people against disease.
Still, the results give Strep A vaccine developers a concrete route to explore: combining a carbohydrate target with a GMMA platform and administering it through mucosal tissue. For a pathogen that still lacks a licensed vaccine, evidence that a needle-free candidate can prompt both local and bodywide immune activity is a meaningful technical milestone.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
